The report provides a detailed analysis essential for establishing a Fidaxomicin production plant. It encompasses all critical aspects necessary for Fidaxomicin production, including the cost of Fidaxomicin production, Fidaxomicin plant cost, Fidaxomicin production costs, and the overall Fidaxomicin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fidaxomicin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Fidaxomicin is a narrow-spectrum antibiotic used for the treatment of Clostridium difficile-related infections. It is widely used as a drug for the treatment of severe gastrointestinal infection caused by Clostridium difficile (C. difficile). It is particularly effective in treating C. difficile-associated diarrhoea, which can occur after the use of broad-spectrum antibiotics.
It is also used in settings where preserving healthy gut bacteria is important, as it has a narrow action that leaves most of the normal flora undisturbed. Fidaxomicin works by inhibiting bacterial RNA synthesis, preventing the bacteria from multiplying and spreading within the intestines. It also plays an important role in infection-control programs by helping reduce the spread of C. difficile in healthcare environments.
The demand for Fidaxomicin is driven by its utilisation as an oral drug for the treatment of severe gastrointestinal bacterial infections, which contributes to its market expansion. Its application as a medication in treating Clostridium difficile (C. difficile) infections further promotes its demand in the medical and pharmaceutical industries. Its ability to work in the gut and combat infection without being absorbed much into the bloodstream and fewer effects on the rest of the body also promotes its demand.
Procurement practices for Fidaxomicin are influenced by various factors, such as production costs, the availability of active pharmaceutical ingredients (APIs), and adherence to stringent regulatory guidelines. Technological advancements in its production processes, along with the need for supplier reliability, sustainability practices, and efficient distribution channels, also play a crucial role in shaping global industrial Fidaxomicin procurement.
Raw Material for Fidaxomicin Production
According to the Fidaxomicin production plant project report, the major raw materials for Fidaxomicin production includes Actinoplans deccanensis or Dactylosporangium aurantiacum.
Production Process of Fidaxomicin
The extensive Fidaxomicin production cost report consists of the following industrial production process:
- Production via Fermentation : The production process of Fidaxomicin begins with cultivating the selected actinomycete strain, usually Actinoplans deccanensis or Dactylosporangium aurantiacum. The strain is cultivated in a controlled fermenter where the organism grows in a nutrient-rich broth and naturally produces the macrolide. Once the fermentation reaches the desired stage, the broth is filtered to separate the cells from the liquid containing the antibiotic. Then, the filtrate goes through solvent extraction to pull out the crude product. Further, purification steps, which involve resin adsorption and careful chromatography, remove impurities without disturbing the delicate structure of the molecule. After the purified compound is collected, it is concentrated, dried, and milled into a stable form to obtain pure Fidaxomicin as the final product.
Fidaxomicin is a narrow-spectrum antibiotic used for treating Clostridium difficile infections. It appears as a pale yellow to orange crystalline powder and is odourless. The molecular formula of Fidaxomicin is C52H74Cl2O18, and its molecular mass is 1058.0 g/mol. Its density is around 1.33 g/cm3, and it is poorly soluble in water. Fidaxomicin has a melting point of around 200-205 degree Celsius and does not have a defined boiling point, as it is unstable at high temperatures. It is not flammable under standard conditions. It can have some side effects, such as nausea, vomiting, and abdominal discomfort. Prolonged use should be avoided to reduce the risk of developing antibiotic resistance. It is also known as lipiarmycin and tiacumicin.